show all | hide all No of entries

Information on EC 3.4.15.1 - peptidyl-dipeptidase A and Organism(s) Homo sapiens and UniProt Accession P12821

for references in articles please use BRENDA:EC3.4.15.1
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EC Tree
     3 Hydrolases
         3.4 Acting on peptide bonds (peptidases)
             3.4.15 Peptidyl-dipeptidases
                3.4.15.1 peptidyl-dipeptidase A
Specify your search results
Select one or more organisms in this record:
This record set is specific for:
Homo sapiens
UNIPROT: P12821 not found.
Word Map
The expected taxonomic range for this enzyme is: Eukaryota, Bacteria
The taxonomic range for the selected organisms is: Homo sapiens
Reaction Schemes
release of a C-terminal dipeptide, oligopeptide-/-Xaa-Yaa, when Xaa is not Pro, and Yaa is neither Asp nor Glu. Thus, conversion of angiotensin I to angiotensin II, with increase in vasoconstrictor activity, but no action on angiotensin II
Synonyms
ACE, ACE-1, ACE2, ACEI, ANCE, angiotensin 1 converting enzyme, angiotensin converting enzyme, angiotensin converting enzyme 1, angiotensin converting enzyme I, angiotensin converting enzyme inhibitor, more
SYNONYM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
ACEI
247
-
angiotensin 1 converting enzyme
-
-
-
-
angiotensin converting enzyme
angiotensin converting enzyme inhibitor
247
-
angiotensin I converting enzyme
247
-
angiotensin I-converting enzyme
angiotensin-converting enzyme
angiotensin-converting enzyme 2
277645
-
angiotensin-converting enzyme-2
247
-
angiotensin-converting-enzyme
247
-
angiotensin-I converting enzyme
247
-
angiotensin-I-converting enzyme
247
-
carboxycathepsin
-
-
-
-
carboxypeptidase, dipeptidyl
-
-
-
-
CD143 antigen
-
-
-
-
Dipeptidyl carboxypeptidase
-
-
-
-
dipeptidyl carboxypeptidase I
-
-
-
-
endothelial cell peptidyl dipeptidase
-
-
-
-
gACE
247
-
germinal ACE
247
-
kininase II
PDH
-
-
-
-
peptidase P
-
-
-
-
peptidyl dipeptidase
peptidyl dipeptidase A
-
-
-
-
peptidyl dipeptidase I
-
-
-
-
peptidyl dipeptidase-4
-
-
-
-
peptidyl dipeptide hydrolase
-
-
-
-
peptidyl-dipeptide hydrolase
-
-
-
-
peptidyldipeptide hydrolase
-
-
-
-
rhACE2
247
-
s-ACE
282623
-
sACE-1
247
-
somatic ACE
somatic angiotensin I-converting enzyme
282623
-
testicular ACE
247
-
testis ACE
282623
-
additional information
247
ACE is a M2 family metallopeptidase
CAS REGISTRY NUMBER
COMMENTARY hide
9015-82-1
-
SUBSTRATE
PRODUCT                       
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
benzyloxycarbonyl-Phe-His-Leu + H2O
?
show the reaction diagram
-
-
-
?
hippuryl-His-Leu + H2O
hippuric acid + His-Leu
show the reaction diagram
-
-
-
?
hippuryl-L-His-L-Leu + H2O
hippuric acid + L-His-L-Leu
show the reaction diagram
-
-
-
-
?
(7-methoxycoumarin-2-acetic acid)-Ala-Ser-Asp-Lys-(N3-(2,4-dinitrophenyl)-L-2,3-diaminopropyl) + H2O
?
show the reaction diagram
-
-
-
?
(7-methoxycoumarin-2-acetic acid)-Ser-Asp-Lys-(N3-(2,4-dinitrophenyl)-L-2,3-diaminopropyl) + H2O
?
show the reaction diagram
-
-
-
?
(7-methoxycoumarin-2-acetyl)-Tyr-Val-Ala-Asp-Ala-Phe-Lys-(2,4-dinitrophenyl)-OH + H2O
?
show the reaction diagram
-
-
-
-
?
(7-methoxycoumarin-4-yl)acetyl-Ala-Ser-Asp-Lys-N3-(2,4-dinitrophenyl)-L-diaminopropionionate + H2O
?
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Ala-Ala-Leu-Ala-Gly-nitrobenzylamide + H2O
?
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Ala-Ala-Tyr-Leu-Ala-Gly-nitrobenzylamide + H2O
?
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Ala-Tyr-Leu-Ala-Gly-nitrobenzylamide + H2O
?
show the reaction diagram
-
-
-
-
?
2-aminobenzoyl-Val-Tyr-Leu-Ala-Gly-nitrobenzylamide + H2O
?
show the reaction diagram
-
-
-
-
?
2-furanacryloyl-Phe-Gly-Gly + H2O
2-furanacryloyl-Phe + Gly-Gly
show the reaction diagram
3-hydroxybutyryl-Gly-Gly-Gly + H2O
3-hydroxybutyryl-Gly + Gly-Gly
show the reaction diagram
-
-
-
-
?
Abz-LFK(Dnp)-OH + H2O
Abz-Leu-Phe + N6-(2,4-dinitrophenyl)-L-lysine
show the reaction diagram
-
-
-
-
?
Abz-SDK(Dnp)P-OH + H2O
Abz-Ser-Asp + Lys(Dnp)-Pro
show the reaction diagram
-
-
-
-
?
Abz-YRK(2,4-dinitrophenyl)P + H2O
?
show the reaction diagram
-
-
-
-
?
amyloid beta-peptide(1-40) + H2O
amyloid beta-peptide(1-7) + amyloid beta-peptide(8-40)
show the reaction diagram
amyloid beta-protein 1-40 + H2O
amyloid beta-peptide(1-7) + amyloid beta-peptide(8-40)
show the reaction diagram
-
ACE cleaves amyloid beta-protein 1-40 between Asp7 and Ser8
-
-
?
amyloid beta-protein 1-42 + H2O
amyloid beta-peptide(1-40) + amyloid beta-peptide(41-42)
show the reaction diagram
-
ACE cleaves amyloid beta-protein 1-42 at multiple sites
-
-
?
amyloid beta-protein 1-42 + H2O
amyloid beta-protein 1-420 + ?
show the reaction diagram
-
angiotensin-converting enzyme converts amyloid beta-protein 1-42 to amyloid beta-protein1-40. ACE regulates Abeta1-42/Abeta1-40 ratio in vivo by converting secreted Abeta1-42 to Abeta1-40 and degrading Abetas.The upregulation of ACE activity can be a novel therapeutic strategy for Alzheimer’s disease
-
-
?
angiotensin (1-9) + H2O
?
show the reaction diagram
-
-
-
-
?
Angiotensin I + H2O
?
show the reaction diagram
-
-
-
-
?
angiotensin I + H2O
angiotensin II + His-Leu
show the reaction diagram
angiotensin I + H2O
angiotensin II + L-His-L-Leu
show the reaction diagram
-
-
-
-
?
Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2 + H2O
Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly + Leu-Met-NH2
show the reaction diagram
-
-
-
-
?
benzoyl-Gly-Gly-Gly + H2O
benzoyl-Gly + Gly-Gly
show the reaction diagram
-
-
-
-
?
benzoyl-Gly-His-Leu + H2O
benzoyl-Gly + His-Leu
show the reaction diagram
-
-
-
-
?
benzoyl-Gly-Phe-Arg + H2O
benzoyl-Gly + Phe-Arg
show the reaction diagram
-
-
-
-
?
benzyloxycarbonyl-Gly-Gly-Gly + H2O
benzyloxycarbonyl-Gly + Gly-Gly
show the reaction diagram
-
-
-
-
?
benzyloxycarbonyl-Leu-Gly-Gly + H2O
benzyloxycarbonyl-Leu + Gly-Gly
show the reaction diagram
-
-
-
-
?
benzyloxycarbonyl-Phe-His-Leu + H2O
benzyloxycarbonyl-Phe + His-Leu
show the reaction diagram
bradykinin + H2O
?
show the reaction diagram
bradykinin + H2O
Phe-Arg + Ser-Pro + Arg-Pro-Pro-Gly-Phe
show the reaction diagram
-
-
-
-
?
furanacryloyl-L-Phe-Gly-Gly + H2O
furanacryloyl-L-Phe + Gly-Gly
show the reaction diagram
-
-
-
-
?
Gly-Gly-Tyr-Arg + H2O
Gly-Gly + Tyr-Arg
show the reaction diagram
-
-
-
?
gonadotropin-releasing hormone + H2O
?
show the reaction diagram
-
a bridging interaction between Arg500 of the N-domain and Arg8 of gonadotropin-releasing hormone that involves a buried chloride ion may account for its role in the specificity of the N-domain for endoproteolytic cleavage of the substrate at the NH2-terminus in vitro
-
-
?
hippuryl-Gly-Gly + H2O
hippuric acid + Gly-Gly
show the reaction diagram
-
-
-
-
?
hippuryl-His-Leu + H2O
hippuric acid + His-Leu
show the reaction diagram
hippuryl-histidyl-leucine + H2O
?
show the reaction diagram
-
-
-
-
?
hippuryl-L-His-L-Leu + H2O
hippuric acid + L-His-L-Leu
show the reaction diagram
-
-
-
-
?
hippuryl-Phe-Arg + H2O
hippuric acid + Phe-Arg
show the reaction diagram
-
-
-
-
?
LEQIYHL + H2O
?
show the reaction diagram
-
-
-
?
Leu5-enkephalin + H2O
Tyr-Gly-Gly + Phe-Leu
show the reaction diagram
-
-
-
-
?
MCA-Ala-Ser-Asp-Lys-Dap(DNP)-OH + H2O
?
show the reaction diagram
angiotensin-converting enzyme
-
-
?
Mca-RPPGFSAFK(Dnp)-OH + H2O
?
show the reaction diagram
-
-
-
-
?
MCA-Tyr-Val-Ala-Asp-Ala-Pro-Lys(DNP)-OH + H2O
?
show the reaction diagram
angiotensin-converting enzyme 2
-
-
?
Met5-enkephalin + H2O
Tyr-Gly-Gly + Phe-Met
show the reaction diagram
-
-
-
-
?
neurotensin + H2O
pGlu-Leu-Tyr-Glu-Asn-Lys-Pro-Arg-Arg-Pro-Tyr + Ile-Leu
show the reaction diagram
-
-
-
-
?
NKLKPSQ + H2O
?
show the reaction diagram
-
-
-
?
NKLKPSQWI + H2O
?
show the reaction diagram
-
-
-
?
NKLKPSQWISL + H2O
?
show the reaction diagram
-
-
-
?
NKLKPSQWISLSD + H2O
?
show the reaction diagram
-
-
-
?
o-aminobenzoyl-FDK-(dinitrophenyl)-P-OH + H2O
o-aminobenzoyl-FD + K-(dinitrophenyl)-P-OH
show the reaction diagram
-
-
-
?
o-aminobenzoyl-FRK-(dinitrophenyl)-P-OH + H2O
o-aminobenzoyl-FR + K-(dinitrophenyl)-P-OH
show the reaction diagram
-
-
-
?
o-aminobenzoyl-GFSPFAQ-(N-2,4-dinitrophenyl)ethylenediamine + H2O
o-aminobenzoyl-GFSPFA + Gln-(N-2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
?
o-aminobenzoyl-GFSPFEQ-(N-2,4-dinitrophenyl)ethylenediamine + H2O
o-aminobenzoyl-GFSPFE + Gln-(N-2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
?
o-aminobenzoyl-GFSPFFQ-(N-2,4-dinitrophenyl)ethylenediamine + H2O
o-aminobenzoyl-GFSPFF + Gln-(N-2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
?
o-aminobenzoyl-GFSPFLQ-(N-2,4-dinitrophenyl)ethylenediamine + H2O
o-aminobenzoyl-GFSPFL + Gln-(N-2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
?
o-aminobenzoyl-GFSPFQQ-(N-2,4-dinitrophenyl)ethylenediamine + H2O
o-aminobenzoyl-GFSPFQ + Gln-(N-2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
?
o-aminobenzoyl-GFSPFRA-(N-2,4-dinitrophenyl)ethylenediamine + H2O
o-aminobenzoyl-GFSPFR + Ala-(N-2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
?
o-aminobenzoyl-GFSPFRF-(N-2,4-dinitrophenyl)ethylenediamine + H2O
o-aminobenzoyl-GFSPFR + Phe-(N-2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
?
o-aminobenzoyl-GFSPFRI-(N-2,4-dinitrophenyl)ethylenediamine + H2O
o-aminobenzoyl-GFSPFR + Ile-(N-2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
?
o-aminobenzoyl-GFSPFRN-(N-2,4-dinitrophenyl)ethylenediamine + H2O
o-aminobenzoyl-GFSPFR + Asn-(N-2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
?
o-aminobenzoyl-GFSPFRQ-(N-2,4-dinitrophenyl)ethylenediamine + H2O
o-aminobenzoyl-GFSPFR + Gln-(N-2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
?
o-aminobenzoyl-GFSPFRR-(N-2,4-dinitrophenyl)ethylenediamine + H2O
o-aminobenzoyl-GFSPFR + Arg-(N-2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
?
o-aminobenzoyl-GFSPFRS-(N-2,4-dinitrophenyl)ethylenediamine + H2O
o-aminobenzoyl-GFSPFR + Ser-(N-2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
?
o-aminobenzoyl-GFSPFSQ-(N-2,4-dinitrophenyl)ethylenediamine + H2O
o-aminobenzoyl-GFSPFS + Gln-(N-2,4-dinitrophenyl)ethylenediamine
show the reaction diagram
-
-
-
?
o-aminobenzoyl-Phe-Arg-Lys(2,4-dinitrophenyl)-Pro-hydroxide + H2O
?
show the reaction diagram
-
-
-
-
?
o-aminobenzoyl-SDK-(dinitrophenyl)-P-OH + H2O
o-aminobenzoyl-SD + K-(dinitrophenyl)-P-OH
show the reaction diagram
-
-
-
?
o-aminobenzoyl-SRK-(dinitrophenyl)-P-OH + H2O
o-aminobenzoyl-SR + K-(dinitrophenyl)-P-OH
show the reaction diagram
-
-
-
?
o-aminobenzoyl-TDK-(dinitrophenyl)-P-OH + H2O
o-aminobenzoyl-TD + K-(dinitrophenyl)-P-OH
show the reaction diagram
-
-
-
?
o-aminobenzoyl-TRK-(dinitrophenyl)-P-OH + H2O
o-aminobenzoyl-TR + K-(dinitrophenyl)-P-OH
show the reaction diagram
-
-
-
?
o-aminobenzoyl-YDK-(dinitrophenyl)-P-OH + H2O
o-aminobenzoyl-YD + K-(dinitrophenyl)-P-OH
show the reaction diagram
-
-
-
?
o-aminobenzoyl-YRK-(dinitrophenyl)-P-OH + H2O
o-aminobenzoyl-YR + K-(dinitrophenyl)-P-OH
show the reaction diagram
-
-
-
?
p-hydroxyhippuryl-His-Leu + H2O
?
show the reaction diagram
-
-
-
?
p-nitrobenzyloxycarbonyl-Gly + H2O
?
show the reaction diagram
-
-
-
-
?
p-nitrobenzyloxycarbonyl-Gly-Gly-Gly + H2O
?
show the reaction diagram
-
-
-
-
?
SLKPSNWLTPSE + H2O
?
show the reaction diagram
-
-
-
?
tert-butoxycarbonyl-Phe-Ala-Pro + H2O
tert-butoxycarbonyl-Phe + Ala-Pro
show the reaction diagram
-
-
-
-
?
Z-Phe-His-Leu + H2O
Z-Phe + His-Leu
show the reaction diagram
-
-
-
-
?
Z-phenylalanyl-histidyl-leucine + H2O
Z-phenylalanine + histidyl-leucine
show the reaction diagram
-
-
-
-
?
[Arg10]angiotensin I + H2O
?
show the reaction diagram
-
-
-
-
?
[Phe9,Arg10]angiotensin I + H2O
?
show the reaction diagram
-
-
-
-
?
[Phe9]angiotensin I + H2O
?
show the reaction diagram
-
-
-
-
?
additional information
?
-
NATURAL SUBSTRATE
NATURAL PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
amyloid beta-peptide(1-40) + H2O
amyloid beta-peptide(1-7) + amyloid beta-peptide(8-40)
show the reaction diagram
-
cleavage at the Asp7-Ser9 bond. Compared with amyloid beta-peptide(1-40), aggregation and cytotoxic effects of the degradation products amyloid beta-peptide(1-7) and amyloid beta-peptide(8-40) are reduced ot virtually absent. The enzyme inhibits aggregation, deposition, and cytotoxicity of amyloid beta-peptide in vitro may affect susceptibility to Alzheimer‘s disease
-
?
amyloid beta-protein 1-40 + H2O
amyloid beta-peptide(1-7) + amyloid beta-peptide(8-40)
show the reaction diagram
-
ACE cleaves amyloid beta-protein 1-40 between Asp7 and Ser8
-
-
?
amyloid beta-protein 1-42 + H2O
amyloid beta-peptide(1-40) + amyloid beta-peptide(41-42)
show the reaction diagram
-
ACE cleaves amyloid beta-protein 1-42 at multiple sites
-
-
?
amyloid beta-protein 1-42 + H2O
amyloid beta-protein 1-420 + ?
show the reaction diagram
-
angiotensin-converting enzyme converts amyloid beta-protein 1-42 to amyloid beta-protein1-40. ACE regulates Abeta1-42/Abeta1-40 ratio in vivo by converting secreted Abeta1-42 to Abeta1-40 and degrading Abetas.The upregulation of ACE activity can be a novel therapeutic strategy for Alzheimer’s disease
-
-
?
angiotensin I + H2O
angiotensin II + His-Leu
show the reaction diagram
angiotensin I + H2O
angiotensin II + L-His-L-Leu
show the reaction diagram
-
-
-
-
?
bradykinin + H2O
?
show the reaction diagram
additional information
?
-
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
CaCl2
-
activates in absence of Cl-, maximal activity at 0.3 mM
Cl-
-
the activity of the C-domain of sACE depends highly on chloride ion concentration and is inactive in its absence, whereas the N-domain can be completely activated at relatively low concentrations of this anion and is still active in the absence of chloride
Na2SO4
-
activates in absence of Cl-
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(2R)-2-((3-[hydroxyl (2-phenyl-(1R)-1-([(benzyloxy) carbonyl]-amino)ethyl)phosphinyl]-2-[(3-phenylisoxazol-5-yl)methyl]-1-oxopropyl)amino)-3-(4-hydroxy-phenyl) propanoic acid
-
-
(2S)-2-((3-[hydroxyl (2-phenyl-(1R)-1-([(benzyloxy) carbonyl]-amino)ethyl)phosphinyl]-2-[(3-phenylisoxazol-5-yl)methyl]-1-oxopropyl)amino)-3-(4-hydroxy-phenyl) propanoic acid
-
-
angiotensin II
-
angiotensin II shows selective competitive inhibition of the carboxy-terminal domain of human somatic ACE
bradykinin potentiating peptide b
-
interaction with sACE in a Zn-dependent manner
-
captopril
enalaprilat
-
the relative potency of the inhibitors in the order of decreasing efficieny is: enalaprilat, lisinopril, captopril. The thermodynamic behaviour of the binding process is analyzed
lisinopril
-
the relative potency of the inhibitors in the order of decreasing efficieny is: enalaprilat, lisinopril, captopril. The thermodynamic behaviour of the binding process is analyzed
ramiprilat
-
the ACE inhibitor-induced dimerization of angiotensin-converting enzyme, via the C domain of the enzyme, represents the initial step in the angiotensin-converting enzyme signaling pathway that involves the activation of the JNK/c-Jun pathway and leads to changes in endothelial cell gene expression
(2S)-2-((3-[hydroxyl(2-phenyl-(1R)-1([(benzyloxy)carbonyl]amino)ethyl)phosphinyl]-(2R)-2-[(3-phenylisoxazol-5-yl)methyl]-1-oxopropyl)amino)-3-phenyl propanoic acid
-
-
(2S)-2-((3-[hydroxyl(2-phenyl-(1R)-1-([(benzyloxy)carbonyl]-amino)ethyl)phosphinyl]-(2R)-2-[(3-phenylisoxazol-5-yl)methyl]-1-oxopropyl)amino) 1H-Indole-3-propanoic acid
-
-
(2S)-2-((3-[hydroxyl(2-phenyl-(1R)-1-([(benzyloxy)carbonyl]-amino)ethyl)phosphinyl]-(2R)-2-[(3-phenylisoxazol-5-yl)methyl]-1-oxopropyl)amino)-3-(4-hydroxy-phenyl) propanoic acid
-
-
(2S)-2-((3-[hydroxyl(2-phenyl-(1R)-1-([(benzyloxy)carbonyl]-amino)ethyl)phosphinyl]-(2S)-2-[(3-phenylisoxazol-5-yl)methyl]-1-oxopropyl)amino) 1H-indole-3-propanoic acid
-
-
(2S)-2-((3-[hydroxyl(2-phenyl-(1R)-1-([(benzyloxy)carbonyl]-amino)ethyl)phosphinyl]-(2S)-2-[(3-phenylisoxazol-5-yl)methyl]-1-oxopropyl)amino)-3-(4-hydroxy-phenyl) propanoic acid
-
-
(2S)-2-([3-(1,1'-biphenyl)-2-([hydroxyl(2-phenyl-(1R)-1-([(benzyloxy)carbonyl]amino)ethyl)phosphinyl]methyl)-1-oxopropyl]-amino) 1H-indole-3-propanoic acid
-
-
(2S)-2-([3-(3'-[1,1'-biphenyl]-4''-yl-4',5'-dihydro-5'-isoxazolyl)-2-([hydroxyl(2-phenyl-(1R)-1-([(benzyloxy)carbonyl]amino)ethyl)-phosphinyl]methyl)-1-oxopropyl]amino) 1H-indole-3-propanoic acid
-
-
(2S)-2-[[(2S)-2-mercapto-3-methylpentanoyl]amino]-3-(1-naphthyl)propanoic acid
-
(2S)-2-[[(2S)-2-mercapto-3-methylpentanoyl]amino]-3-(2-naphthyl)propanoic acid
-
-
(2S)-2-[[(2S)-2-mercapto-3-methylpentanoyl]amino]-3-phenylpropanoic acid
-
(2S)-2-[[(2S)-2-mercapto-3-methylpentanoyl]amino]propanoic acid
-
(2S)-3-(4-hydroxyphenyl)-2-[[(2S)-2-mercapto-3-methylpentanoyl]amino]propanoic acid
-
(2S)-3-biphenyl-2-yl-2-[[(2S)-3-methyl-2-sulfanylpentanoyl]amino]propanoic acid
-
-
(2S)-3-biphenyl-3-yl-2-[[(2S)-3-methyl-2-sulfanylpentanoyl]amino]propanoic acid
-
-
(2S)-3-biphenyl-4-yl-2-[(2-mercapto-2-methylpropanoyl)amino]propanoic acid
-
(2S)-3-biphenyl-4-yl-2-[(mercaptoacetyl)amino]propanoic acid
-
(2S)-3-biphenyl-4-yl-2-[[(2S)-2-mercaptobutanoyl]amino]propanoic acid
-
(2S)-3-biphenyl-4-yl-2-[[(2S)-2-mercaptopropanoyl]amino]propanoic acid
-
(2S)-3-biphenyl-4-yl-2-[[(2S)-3-methyl-2-sulfanylpentanoyl]amino]propanoic acid
-
-
(5S)-5-[(N-benzoyl)-amino]-4-oxo-6-phenyl-hexanoyl-L-phenylalanine
-
phosphinic peptide inhibitor kAF
(5S)-5-[(N-benzoyl)amino]-4-oxo-6-phenylhexanoyl-L-phenylalanine
-
the inhibitor has a 30fold higher affinity for the C domain than for the N domain of ACE
(5S)-5-[(N-benzoyl)amino]-4-oxo-6-phenylhexanoyl-L-tryptophan
(pE)KWAP
-
-
(pE)WPRPQIPP
-
-
1,10-phenanthroline
-
-
1-Fluoro-2,4-dinitrobenzene
-
1 mM, 96% inhibition of N-domain ACE
1-[(5S)-4-oxo-6-phenyl-5-[(phenylcarbonyl)amino]hexanoyl]-L-proline
-
1-[(5S)-5-[(tert-butoxycarbonyl)amino]-4-oxo-6-phenylhexanoyl]-L-proline
-
15 B1
-
-
15 B2
-
-
2,3-dimercapto-1-propanol
-
-
2-(benzyloxy)-N-[(2S)-3-methyl-2-sulfanylpentanoyl]-L-phenylalanine
-
-
2-mercaptoethanol
-
-
2-[([2-[(1-[[(benzyloxy)carbonyl]amino]-2-phenylethyl)(hydroxy)phosphoryl]cyclopentyl]carbonyl)amino]-3-(2,3-dihydro-1H-indol-3-yl)propanoate
-
-
3-(benzyloxy)-N-[(2S)-3-methyl-2-sulfanylpentanoyl]-L-phenylalanine
-
-
3-mercapto-2-D-methylpropanoyl-L-Pro
-
i.e. SQ-14,225
8-hydroxyquinoline
-
-
A 58365A
-
-
A 58365B
-
-
Ala-Gly-Ser
-
-
Ala-Gly-Ser-Pro
-
-
Ala-Gly-Ser-Ser
-
-
Ala-His-Ser-Tyr
-
a noncompetitive inhibitor, the peptide is resistant to further degenration by pepsin, trypsin, and chymotrypsin
Ala-Leu-Pro-His-Ala
-
-
Ala-Phe
-
-
Ala-Pro-Gly-Ala-Gly-Val-Tyr
-
-
Ala-Trp-Pro-Phe
-
-
Ala-Tyr
-
-
Ala-Val-Val
-
-
alcacepril
-
synthetic ACE inhibitor and antihypertensive drug
ancovenin
-
-
angiotensin converting enzyme inhibitor
-
ACE-I, inhibition is impacting both the renin-angiotensin cascade and the degradation metabolism of bradykinin, inhibition mechanism, overview. ACE-I is used as therapeutic agent in congestive heart failure, diabetic nephropathy, hypertension, and coronary artery disease. ACE-I medications can induce chronic cough, hypotension, hyperkalemia, bone marrow depression, angioedema, and rarely, hepatic failure. Angioedema involves a subcutaneous swelling reaction that evolves over several hours and is not associated with itching or pain, pathomechanism, detailed overview
-
angiotensin I
-
-
angiotensin I converting enzyme inhibitory peptides
-
from wheat milling byproducts by proteolysis through aspartic proteases, optimally produced at pH 3.2. Milled whole grain, bran, shorts, and red dog acquire ACE inhibitory activity though water soaking treatment, preparation of shorts exhibits the strongest inhibitory activity with an IC50 value of 0.08 mg/ml, overview
-
angiotensin I-converting enzyme inhibitory peptides
-
i.e. ACE-Is, from enzymatic hydrolysates of cuttlefish, Sepia officinalis, muscle proteins, generated by the crude enzyme from Bacillus mojavensis A21, show 87.11% inhibition at 2 mg/ml, mass spectrometric analysis, overview
-
angiotensin II
-
-
angiotensin-converting enzyme inhibitor
-
ACEi, induces angioedema, a non-allergic bradykinin-induced drug side-effect and clinical life-threatening problem, overview. ACE insertion/deletion and bradykinin B2 receptor polymorphisms are not involved in the development of ACEi-induced angio-oedema
-
Arg-Pro-Pro
-
inhibition of enzyme form I and II, enzyme form III is not inhibited
Asn-Phe
-
-
Asn-Trp-Gly-Pro-Leu-Val
-
-
Asn-Tyr
-
-
Asp-Gly
-
-
Asp-Ile-Gly-Tyr-Tyr
-
-
Asp-Leu-Pro
-
-
Asp-Phe-Gly
-
-
Asp-Tyr-Val-Gly-Asn
-
-
aspergillomarasmine A
-
-
aspergillomarasmine B
-
-
benazepril
benzapril
-
-
bradykinin
-
-
bradykinin potentiator C
bradykinin-potentiating factor SQ 20881
-
-
bradykinin-potentiating peptide 9a
-
-
captopril
CGS-35066
-
-
chitooligosaccharide derivatives
-
i.e. COS, chitosan derivatives, polycationic polymers comprised principally of glucosamine units, generated via either chemical or enzymatic hydrolysis of chitosan. ACE inhibitory activity of hetero-COS, derived from crab chitin, is dependent on the degree of deacetylation of chitosan
-
cilazapril
-
-
D-3-thio-2-methylpropanoyl-Pro
-
-
D-Cys-L-Pro
-
competitive to hippuryl-His-Leu
dieckol
-
deribed from Ecklonia stolonifera
dithiothreitol
-
-
DQVFPMNPPK
-
-
eckol
-
derived from Ecklonia stolonifera
enalapril
enalaprilat
-
-
enalaprilate
enaprilat
-
-
FDKPVSPL
-
-
foroxymithine
-
-
fosinopril
Gly-Asp-Ala-Pro
-
-
Gly-Glu-Pro
-
-
Gly-Gly-Val-Ile-Pro-Asn
-
-
Gly-His-Gly
-
-
Gly-Pro-Pro
-
-
Gly-Tyr
-
-
Gly-Val-His-His-Ala
-
-
guanethidine
-
weak
H2S
-
Zn2+ but not Cd2+, Ca2+ or Mg2+ could counteract the inhibitory effect
His-His-Leu
-
-
Ile-Ala
-
-
Ile-Ala-Tyr-Lys-Pro-Ala-Gly
-
-
Ile-Ala-Val
-
-
Ile-Asn-Ser-Gln
-
-
Ile-Gln-Pro
-
-
Ile-Glu-Pro
-
molecular docking analysis at the active site of testis ACE, overview
Ile-Glu-Trp
-
-
Ile-Glu-Tyr
-
molecular docking analysis at the active site of testis ACE, overview
Ile-Lys-Pro
-
a potent competitive inhibitor, molecular docking analysis at the active site of testis ACE, overview
Ile-Lys-Trp
-
molecular docking analysis at the active site of testis ACE, overview
Ile-Lys-Tyr
-
molecular docking analysis at the active site of testis ACE, overview
Ile-Phe-Leu
-
-
Ile-Pro-Pro
Ile-Pro-Pro-Gly-Val-Pro-Tyr
-
-
Ile-Pro-Pro-Gly-Val-Pro-Tyr-Trp-Thr
-
-
Ile-Thr-Phe
-
-
Ile-Trp
-
-
Ile-Trp-His-His-Thr
-
-
Ile-Tyr-Leu-Leu
-
-
Ile-Val-Tyr
-
-
imidapril
-
-
ITTNPY
-
-
K-13
-
-
K-26
-
-
-
KAPVA
-
a peptide derived from muscle titin
L-681,176
-
-
L-Ala-L-Trp
-
-
L-Cys-L-Pro
-
-
L-Val-L-Phe
-
-
L-Val-L-Tyr
-
-
Leu-Ala-Ile-pro-Val-Asn-Lys-Pro
-
-
Leu-Arg-Ile-Pro-Val-Ala
-
-
Leu-Arg-Pro
-
-
Leu-Gln-Pro
-
-
Leu-Gly-Ile
-
-
Leu-Phe
-
-
Leu-Tyr
-
-
LFDKPVSPL
-
-
lisinopril
lisW-S
-
a C-domain-selective derivative of the drug lisinopril. The compound shows a 258fold domain-selectivity for the C-domain compared to the N-domain, that is largely due to the co-operative effect of C-domain-specific residues in the S2' subsite. Interactions in the active site: comparison between N- and C-domain residues, overview
LKPNM
-
-
LRPARPTSPP
-
-
LRPARPTSPPA
-
-
Lys-Asp-Tyr-Arg-Leu
-
-
Lys-Leu-Pro-Arg-Gly-Thr-Leu-Phe
-
-
Met-Arg-Trp
-
-
Met-Arg-Trp-Arg-Asp
-
-
MLGQTPT
-
-
muracein A
-
-
muracein B
-
-
muracein C
-
-
MYPGIA
-
-
N-(3-{[(1R)-1-{[(benzyloxy)carbonyl]amino}-2-phenylethyl](hydroxy)phosphoryl}-2-{[3-(biphenyl-4-yl)-4,5-dihydro-1,2-oxazol-5-yl]methyl}propanoyl)-L-tryptophan
-
-
N-[(2S)-3-methyl-2-sulfanylpentanoyl]-2-phenoxy-L-phenylalanine
-
-
N-[(2S)-3-methyl-2-sulfanylpentanoyl]-3-phenoxy-L-phenylalanine
-
-
N-[(2S)-3-methyl-2-sulfanylpentanoyl]-O-phenyl-L-tyrosine
-
-
N-[(2S)-3-methyl-2-sulfanylpentanoyl]-O-[4-(trifluoromethyl)benzyl]-L-tyrosine
-
-
N-[(5S)-4-oxo-6-phenyl-5-[(phenylcarbonyl)amino]hexanoyl]-L-phenylalanine
-
N-[(5S)-4-oxo-6-phenyl-5-[(phenylcarbonyl)amino]hexanoyl]-L-tryptophan
-
N-[(5S)-5-[(tert-butoxycarbonyl)amino]-4-oxo-6-phenylhexanoyl]-L-phenylalanine
-
N-[(5S)-5-[(tert-butoxycarbonyl)amino]-4-oxo-6-phenylhexanoyl]-L-tryptophan
-
N-[(S)-1-(ethoxycarbonyl)-3-phenylpropyl]-L-alanyl-L-proline
-
i.e. MK 421. Effect of the inhibitor on the components of the renin system in healthy subjects : the drug has a prolonged duration of action and effectively reduces plasma converting enzyme activity, angiotensin II and aldosterone levels and thereby increases sodium diuresis
N-[1(S)-carboxy-5-aminopentyl]glycylglycine
-
weak competitive
N-[3-{[(1R)-1-{[(benzyloxy)carbonyl]amino}-2-phenylethyl](hydroxy)phosphoryl}-2-(biphenyl-4-ylmethyl)propanoyl]-L-tryptophan
-
-
N-{(2R)-3-{[(1R)-1-{[(benzyloxy)carbonyl]amino}-2-phenylethyl](hydroxy)phosphoryl}-2-[(3-phenyl-1,2-oxazol-5-yl)methyl]propanoyl}-L-tyrosine
-
-
N-{(2S)-3-{[(1R)-1-{[(benzyloxy)carbonyl]amino}-2-phenylethyl](hydroxy)phosphoryl}-2-[(3-phenyl-1,2-oxazol-5-yl)methyl]propanoyl}-L-tryptophan
-
-
N2-[(S)-1-carboxy-3-phenylpropyl]-L-lysyl-L-proline
-
effect of the inhibitor on the components of the renin system in healthy subjects : the drug has a prolonged duration of action and effectively reduces plasma converting enzyme activity, angiotensin II and aldosterone levels and thereby increases sodium diuresis
O-(2,4-difluorobenzyl)-N-[(2S)-3-methyl-2-sulfanylpentanoyl]-L-tyrosine
-
-
O-(3,4-difluorobenzyl)-N-[(2S)-3-methyl-2-sulfanylpentanoyl]-L-tyrosine
-
-
O-(4-fluorobenzyl)-N-[(2S)-3-methyl-2-sulfanylpentanoyl]-L-tyrosine
-
-
O-benzyl-N-[(2S)-3-methyl-2-sulfanylpentanoyl]-L-tyrosine
-
-
O-[3,5-bis(trifluoromethyl)benzyl]-N-[(2S)-3-methyl-2-sulfanylpentanoyl]-L-tyrosine
-
omapatrilat
-
-
PARPTSPP
-
-
perindopril
perindoprilat
-
-
pGlu-Asn-Trp-Pro-His-Pro-Gln-Ile-Pro-Pro
-
-
pGlu-Gly-Leu-Pro-Pro-Arg-Pro-Lys-Ile-Pro-Pro
-
-
pGlu-Gly-Leu-Pro-Pro-Gly-Pro-Pro-Ile-Pro-Pro
-
-
pGlu-Trp-Pro-Arg-Pro-Gln-Ile-Pro-Pro
-
-
Phe-Gly-Gly
-
-
Phe-Phe-Leu
-
-
Phe-Tyr
-
-
Phe-Val-Asn-Pro-Gln-Ala-Gly-Ser
-
-
phenacein
-
-
phlorofucofuroeckol A
-
derived from Ecklonia stolonifera
phlorotannins
-
e.g. from Ahnfeltiopsis flabelliformis, Ecklonia cava, Ecklonia stolonifera, Pelvetia siliqousa, and Undaria pinnatifida, phenolic compounds formed by the polymerization of phloroglucinol or defined as 1,3,5-trihydroxybenzene monomer units and biosynthesized through the acetate-malonate pathway. They are highly hydrophilic components with a wide range of molecular sizes ranging between 126-650 kDa. A closed ring dibenzo-1,4-dioxin moiety may be crucial for ACE inhibitory effects
-
phosphoramidon
-
-
Pro-Asn-Asn-Lys-Pro-Phe-Gln
-
-
Pro-Ser-Tyr
-
-
PTPVP
-
a peptide derived from muscle titin
Pyr-Trp-Pro-Arg-Pro-Gln-Ile-Pro
-
therapeutical useful
quinapril
quinaprilat
-
-
ramipril
ramiprilat
rampiril
-
-
RPARPTSPP
-
-
RVAPEEHPT
-
-
RXP407
-
-
RXPA380
SCH 54470
-
-
Ser-Phe
-
-
Ser-Pro-Pro
-
-
Ser-Trp-Ser-Phe
-
-
Ser-Tyr
-
-
snake venom peptide
-
-
-
soymilk protein proteolytic peptides
-
generated by proteolytic action of Lactobacilli and Bifidobacterium, which is increased in presence of fructooligosaccharides. The peptides show inhibitory activity to ACE, with IC50 values of 0.02 to 0.17 mg/ml, and antihypertensive effect in vivo, overview
-
spirapril
-
-
SSYVHLRPARPTSPP
-
-
talopeptin
-
-
tannin
-
-
-
temocapril
-
chronic treatment with temocapril improves the carotid arterial stiffness in healthy, normotensive elderly, and hence may reduce their risk for cardiovascular disease
Teprotide
Thr-Ala-Pro-Tyr
-
-
Thr-Gln-Val-Tyr
-
-
Thr-Tyr-Leu-Gly-Ser
-
-
Thr-Val-Pro-Tyr
-
-
Thr-Val-Tyr
-
-
Thr-Val-Val-Pro-Gly
-
-
trandolapril
-
the angiotensin-converting enzyme inhibitor has no effect on the rate of endothelial apoptosis in vitro in HUVEC cells
trandolaprilat
-
-
Trp-Leu
-
-
Trp-Val-Pro-Ser-Val-Tyr
-
-
Tyr-Ala-Leu-Pro-His-Ala
-
-
Tyr-Gln-Tyr
-
-
Tyr-Leu
-
-
Tyr-Leu-Ala-Gly-Asn-Gln
-
-
Tyr-Pro-Lys
-
-
Tyr-Tyr-Ala-Pro-Phe
-
-
Tyr-Tyr-Ala-Pro-Phe-Asp-Gly-Ile-Leu
-
-
Tyr-Val-Val-Phe-Lys
-
-
Urea
-
weak
Val-Ile-Glu-Lys-Tyr-Pro
-
-
Val-Leu-Ile-Val-Pro
-
-
Val-Lys
-
-
Val-Met-Asp-Lys-Pro-Gln-Gly
-
-
Val-Phe
-
-
Val-Phe-Pro-Ser
-
-
Val-Phe-Pro-Tyr
-
-
Val-Pro-Pro
Val-Thr-Pro-Ala-Leu-Arg
-
-
Val-Thr-Val-Asn-Pro-Tyr-Lys-Trp-Leu-Pro
-
-
Val-Trp
-
-
VAPEEHPT
-
-
VIPEL
-
-
warfarin
-
-
WF-10,129
-
-
YVHLRPARPTSPP
-
-
zofenpril
-
-
[CB-TE2A]1--lisinopril
-
-
-
[Co-DOTA]1--lisinopril
-
-
-
[Co-EDTA]1--lisinopril
-
-
-
[Co-GGH]0-lisinopril
-
-
[Co-NTA]0-lisinopril
-
-
[Cu-CB-TE2A]1+-lisinopril
-
-
-
[Cu-DOTA]1--lisinopril
-
-
-
[Cu-EDTA]1--lisinopril
-
-
-
[Cu-GGH]0-lisinopril
-
-
[Cu-NTA]0-lisinopril
-
-
[DOTA]1--lisinopril
-
-
-
[EDTA]3-lisinopril
-
-
-
[Fe-CB-TE2A]2+-lisinopril
-
-
-
[Fe-DOTA]0-lisinopril
-
-
-
[Fe-EDTA]0-lisinopril
-
-
-
[Fe-NTA]1+-lisinopril
-
-
[GGH]1+-lisinopril
-
-
[Ni-CB-TE2A]1+-lisinopril
-
-
-
[Ni-DOTA]1--lisinopril
-
-
-
[Ni-EDTA]1--lisinopril
-
-
-
[Ni-GGH]0-lisinopril
-
-
[Ni-NTA]0-lisinopril
-
-
[NTA]2-lisinopril
-
-
[[(2S)-2-mercapto-3-methylpentanoyl]amino]acetic acid
-
-
additional information
-
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE